AKBLF 14.00 Stock Price ALK-Abelló A/S
Range: | 11.0-27.0328 | Vol Avg: | 5 | Last Div: | 0 | Changes: | 2.83 |
Beta: | 0.61 | Cap: | 4.91B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Mon Nov 16 2009 | Empoloyees: | 2824 |
CUSIP: | | CIK: | | ISIN: | DK0061802139 | Country: | DK |
CEO: | Mr. Peter Halling | Website: | https://www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.